News Image

Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.

By Mill Chart

Last update: Jan 2, 2024

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

Exploring Why NASDAQ:AMPH Holds Promise for Growth Investors.

  • AMPHASTAR PHARMACEUTICALS IN has a healthy Return on Equity(ROE) of 22.72%. This demonstrates the company's efficient utilization of capital and indicates its commitment to driving profitability.
  • AMPHASTAR PHARMACEUTICALS IN has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
  • The 1-year revenue growth of AMPHASTAR PHARMACEUTICALS IN (24.0%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
  • AMPHASTAR PHARMACEUTICALS IN has demonstrated strong q2q revenue growth of 50.37%, suggesting a favorable trend in the company's financials and indicating the potential for continued expansion.
  • The operating margin of AMPHASTAR PHARMACEUTICALS IN has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
  • AMPHASTAR PHARMACEUTICALS IN has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
  • The EPS of AMPHASTAR PHARMACEUTICALS IN has exhibited growth from one quarter to another (Q2Q), with a 203.0% increase. This underscores the company's ability to generate higher earnings and improve its financial standing.
  • The average next Quarter EPS Estimate by analysts was adjusted by 23.76%, reflecting the evolving market expectations for the company's EPS growth.
  • The quarterly earnings of AMPHASTAR PHARMACEUTICALS IN have shown a 203.0% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • accelerating EPS growth for AMPHASTAR PHARMACEUTICALS IN: the current Q2Q growth of 203.0% exceeds the previous year Q2Q growth of -17.39%.

What else is there to say on the fundamentals of NASDAQ:AMPH?

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

Taking everything into account, AMPH scores 7 out of 10 in our fundamental rating. AMPH was compared to 204 industry peers in the Pharmaceuticals industry. AMPH has an excellent profitability rating, but there are some minor concerns on its financial health. AMPH is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make AMPH a good candidate for value and growth investing.

For an up to date full fundamental analysis you can check the fundamental report of AMPH

Our Lois Navellier screen will find you more ideas suited for growth investing.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (5/24/2024, 7:13:49 PM)

After market: 43 -0.26 (-0.6%)

43.26

-0.09 (-0.21%)

AMPH News

News Image12 days ago - InvestorPlacePatent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

News Image13 days ago - ChartmillExploring NASDAQ:AMPH's growth characteristics.

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations

News Image19 days ago - InvestorPlaceAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image19 days ago - BusinessInsiderAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amphastar Pharma (NASDAQ:AMPH) just reported results for the first quarter of 2...

News Imagea month ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Image2 months ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image3 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image3 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image3 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image4 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image4 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

AMPH Links
Follow us for more